TOKYO, Nov 17 (Reuters) - Japan's Nikkei share average
closed at a 29-year high on Tuesday as investors cheered news of
another potential coronavirus vaccine that re-ignited hopes of a
swift global recovery.
The Nikkei share average rose 0.42% to 26,014.62,
its highest close since May 1991. The broader Topix
added 0.15% to 1,734.39, after having slipped into negative
territory in morning trade.
Investor sentiment was given a boost when Moderna Inc
said its experimental COVID-19 vaccine was 94.5%
effective in preventing infection based on interim late-state
data.
Still, downturn risks remain as investors turned cautious
after the index rallied sharply by more than 13% this month, and
as new coronavirus cases have been surging both at home and
abroad, analysts said.
The benchmark index had closed at a 29-year high on Monday
as well after the economy posted its first expansion in four
quarters.
"The market has been overheated by a high-paced rise, and it
would be no wonder if stocks go into correction at any time in
the short term," said Maki Sawada, equity market strategist at
Nomura Securities.
The S&P 500 and Dow Jones industrial average notched record
closing highs on Monday after Moderna Inc became the
second U.S. drugmaker to report trial results that far exceed
expectations.
Around two-thirds of the 33 sector sub-indexes on the Tokyo
exchange traded higher.
The airline sector led gains, climbing 3.96%, with ANA
Holdings and Japan Airlines adding 4.16% and
3.72%, respectively.
Other cyclical sectors followed, with miners,
insurers and iron and steel rising between
2.1% and 3.4%.
Semiconductor Tokyo Electron rose 1.32% to a record
high, taking positive cues from its U.S. peers.
Nikkei's heavyweight Fanuc Corp rose nearly 1.5%,
helped by upbeat industrial output data from China and the
formation of a regional trade bloc comprising 15 Asia-Pacific
economies.
The Mothers Index of start-up firm shares bucked the
overall firmness and dropped 3.63%.
(Reporting by Eimi Yamamitsu and Tokyo markets team; Editing by
Ramakrishnan M. and Sherry Jacob-Phillips)